Guerbet: Guerbet Strengthens Its Executive Committee With Two New Appointments to Accelerate Its Commercial and Industrial Development
Guerbet: Guerbet Strengthens Its Executive Committee With Two New Appointments to Accelerate Its Commercial and Industrial Development
Raoul Bernhardt - Director of Industrial OperationsGuerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development
Guerbet通过两项新任命加强其执行委员会，以加快其商业和工业发展
- Dan Raffi appointed Director of Commercial Operations
- Raoul Bernhardt appointed Director of Industrial Operations
- 丹·拉菲被任命为董事商业运营主管
- 拉乌尔·伯恩哈特被任命为工业运营的董事
Villepinte, 10 July 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the strengthening of its management team with two appointments. Dan Raffi and Raoul Bernhardt have joined the Group as Director of Commercial Operations and Director of Industrial Operations respectively. They will both become members of Guerbet's Executive Committee
维尔品特，2023年7月10日：Guerbet(FR0000032526 GBT)是一家全球医学成像造影剂和解决方案专家，该公司宣布通过两项任命来加强其管理团队。丹·拉菲和拉乌尔·伯恩哈特已分别以商业运营董事和工业运营董事的身份加入该集团。他们都将成为格尔贝特执行委员会的成员
Dan RAFFI - Director of Commercial Operations
丹·拉菲--董事商业运营
Raoul Bernhardt - Director of Industrial Operations
拉乌尔·伯恩哈特--工业运营的董事
Guerbet's Executive Committee now has 9 members:
格尔贝执行委员会现在有9名成员：
- David Hale, Chief Executive Officer
- Charlotte Bamière, Director of Legal Affairs
- Raoul Bernhardt, Director of Industrial Operations
- Philippe Bourrinet, Director of Development, Medical & Regulatory Affairs, and Group Chief Pharmacist
- Valérie Brissart, Director of Diagnostic Imaging
- Jérôme Estampes, Chief Financial Officer and Senior VP Business Development and Licensing
- Leïla Mechaï, Director of Human Resources and Corporate Social Responsibility
- François Nicolas, Director of R&D, R&I and Chief Digital Officer
- Dan Raffi, Director of Commercial Operations
- 首席执行官David·黑尔
- 夏洛特·巴米·̀Re，董事法律事务
- 拉乌尔·伯恩哈特，董事工业运营
- 菲利普·布尔里内，董事发展、医疗和监管事务主管，集团首席药剂师
- 诊断成像的淡水河谷́Rie Brissart，董事
- JÉrôMe Estanpe，首席财务官兼业务开发和许可高级副总裁
- 人力资源与企业社会责任董事总监Leïla Mechaï
- 研发、R&I公司董事研发总监兼首席数字官Frçois Nicolas
- 丹·拉菲，董事商业运营
Upcoming events:
即将举行的活动：
Publication of first-half annual revenue
20 July 2023 after trading
公布上半年年度收入
2023年7月20日盘后
About Guerbet
关于格尔贝
At Guerbet, we build lasting relationships so that we enable people to live better. That is our purpose. We are a world leader in medical imaging, offering a complete range of pharmaceutical products, medical devices, and digital and AI solutions for diagnostic and interventional imaging. Pioneers in contrast media for 95 years, with more than 2,830 employees worldwide, we are constantly innovating and devote 8% to 10% of our revenue to research and development in five centres in France, Israel, and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €753 million in revenue in 2022. For more information, please visit .
在格尔贝，我们建立持久的关系，让人们生活得更好。这就是我们的目标。我们是医疗成像领域的世界领先者，提供全套药品、医疗设备以及用于诊断和介入成像的数字和人工智能解决方案。我们作为对比媒体的先驱已有95年的历史，在全球拥有超过2,830名员工，我们不断创新，并将8%至10%的收入投入法国、以色列和美国的五个中心的研发。Guerbet(GBT)在巴黎泛欧交易所(B-中型股)上市，2022年创造了7.53亿欧元的收入。欲了解更多信息，请访问。
Attachment
依附
- 2023 07 10 - GUERBET - Appointments in Executive Committee
- 2023 07 10-Guerbet-执行委员会成员任命
